Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mo-Rez plus bevacizumab versus platinum doublet plus bevacizumab in platinum-sensitive recurrent ovarian cancer
jRCT2031260504Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of mocertatug rezetecan, bevacizumab, carboplatin, paclitaxel, gemcitabine and 1 more in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival by blinded independent central review. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mocertatug rezetecanbevacizumabcarboplatinpaclitaxelgemcitabine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on jRCT2031260504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260504.